| Genetic and functional drivers of diffuse large B cell lymphoma A Reddy, J Zhang, NS Davis, AB Moffitt, CL Love, A Waldrop, S Leppa, ... Cell 171 (2), 481-494. e15, 2017 | 994 | 2017 |
| Immunogenomic landscape of hematological malignancies O Dufva, P Pölönen, O Brück, MAI Keränen, J Klievink, J Mehtonen, ... Cancer Cell 38 (3), 380-399. e13, 2020 | 139 | 2020 |
| Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma L Meriranta, A Alkodsi, A Pasanen, M Lepistö, P Mapar, YN Blaker, ... Blood, The Journal of the American Society of Hematology 139 (12), 1863-1877, 2022 | 56 | 2022 |
| Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis S Leppä, J Jørgensen, A Tierens, L Meriranta, I Østlie, P de Nully Brown, ... Blood advances 4 (9), 1906-1915, 2020 | 46 | 2020 |
| Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes A Alkodsi, A Cervera, K Zhang, R Louhimo, L Meriranta, A Pasanen, ... Leukemia 33 (11), 2662-2672, 2019 | 30 | 2019 |
| Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma L Meriranta, A Pasanen, A Alkodsi, J Haukka, ML Karjalainen-Lindsberg, ... Blood advances 4 (15), 3742-3753, 2020 | 25 | 2020 |
| Deltex-1 mutations predict poor survival in diffuse large B-cell lymphoma L Meriranta, A Pasanen, R Louhimo, A Cervera, A Alkodsi, M Autio, ... Haematologica 102 (5), e195, 2017 | 23 | 2017 |
| Integrative genetic and clinical analysis through whole exome sequencing in 1001 diffuse large B cell lymphoma (DLBCL) patients reveals novel disease drivers and risk groups J Zhang, A Reddy, C Love, AB Moffitt, D Rajagopalan, S Leppä, ... Blood, The Journal of the American Society of Hematology 128 (22), 1087-1087, 2016 | 8 | 2016 |
| ctDNAtools: An R package to work with sequencing data of circulating tumor DNA A Alkodsi, L Meriranta, A Pasanen, S Leppä bioRxiv, 2020.01. 27.912790, 2020 | 3 | 2020 |
| Low expression and somatic mutations of the KLHL6 gene predict poor survival in patients with activated b-cell like diffuse large B-cell lymphoma L Meriranta, A Pasanen, A Cervera, H Holte Jr, R Lehtonen, S Hautaniemi, ... Blood 128 (22), 2926, 2016 | 3 | 2016 |
| Venetoclax, lenalidomide and rituximab for patients with relapsed or refractory mantle cell lymphoma-the nordic lymphoma group NLG-MCL7 (VALERIA) phase Ib-II trial M Jerkeman, A Kolstad, M Hutchings, A Pasanen, L Meriranta, ... Blood 140 (Supplement 1), 184-185, 2022 | 2 | 2022 |
| The DLBCL90 gene‐expression assay identifies double‐hit lymphomas with high sensitivity in patients from two phase II clinical trials with high‐risk diffuse large B‐cell lymphoma KT Isaksen, K Beiske, EB Smeland, J Jørgensen, M Brodtkorb, ... EJHaem 2 (1), 104-108, 2021 | 2 | 2021 |
| Integrative Analysis of 1001 Diffuse Large B Cell Lymphoma Identifies Novel Oncogenic Roles for Rhoa J Zhang, A Reddy, N Davis, A Moffitt, C Love, A Waldrop, S Leppa, ... Blood 130 (Supplement 1), 37-37, 2017 | 2 | 2017 |
| B-solulymfoomien geenivirheiden kliininen merkitys L Pasanen, L Meriranta, S Leppä | 2 | 2017 |
| MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial M Jerkeman, A Kolstad, M Hutchings, A Pasanen, L Meriranta, ... Blood advances 8 (2), 407-415, 2024 | 1 | 2024 |
| BIOMARKER‐DRIVEN TREATMENT STRATEGY IN HIGH‐RISK LARGE B‐CELL LYMPHOMA (NLG‐LBC‐06 PHASE II TRIAL): IMPACT OF CTDNA AND TP53 ABERRATIONS ON CLINICAL OUTCOME S Leppa, L Meriranta, M Arffman, J Jørgensen, M Karjalainen‐Lindsberg, ... Hematological Oncology 41, 51-52, 2023 | 1 | 2023 |
| Serum Proteome Profiling Reveals Inflammatory, Molecular and Prognostic Information Beyond the Ctdna in Aggressive B-Cell Lymphomas M Arffman, L Meriranta, H Holte, J Jørgensen, PDN Brown, S Jyrkkio, ... Blood 140 (Supplement 1), 1316-1317, 2022 | 1 | 2022 |
| Biomarker-Driven Treatment Strategy in High-Risk Large B-Cell Lymphoma: Final Results of a Nordic Phase 2 Study S Leppa, JM Jørgensen, ML Karjalainen-Lindsberg, K Beiske, ... Blood 140 (Supplement 1), 1768-1769, 2022 | 1 | 2022 |
| The DLBCL90 Double-Hit Gene Expression Signature Is Not Associated with Inferior Survival in Young High-Risk Patients with Diffuse Large B-Cell Lymphoma Treated with Dose … KT Isaksen, K Beiske, EB Smeland, J Jørgensen, M Brodtkorb, ... Blood 134, 1485, 2019 | 1 | 2019 |
| Genomic profiling of circulating tumor DNA reveals patterns of response and refractoriness in aggressive B-cell lymphoma-a nordic lymphoma group correlative study L Meriranta, A Alkodsi, A Pasanen, M Lepistö, YN Blaker, M Autio, ... Blood 134, 1481, 2019 | 1 | 2019 |
